Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Rheumatology Reports
Erschienen in: Current Rheumatology Reports 2/2010

01.04.2010

The Role of Uric Acid and Other Crystals in Osteoarthritis

verfasst von: Johannes Nowatzky, Rennie Howard, Michael H. Pillinger, Svetlana Krasnokutsky

Erschienen in: Current Rheumatology Reports | Ausgabe 2/2010

Einloggen, um Zugang zu erhalten

Abstract

Clinicians have long assumed that an association exists between crystal arthropathies and the presence of osteoarthritis (OA). However, studies establishing an independent association between calcium pyrophosphate or uric acid crystal disease and OA are sparse. Even less is known about a possible pathogenic relationship. Whereas some studies suggest that the relationships between crystals and OA may not be incidental and that crystal deposition may contribute to the onset and/or acceleration of OA joint damage, other authors have challenged this assertion. In this review, we provide an overview of past and current research elucidating the role of crystal deposition, including monosodium urate, calcium pyrophosphate, and other crystals, in OA. Given the clinical frequency of gout and that agents exist to modulate serum UA levels, special attention is given to the role of monosodium urate crystals.
Literatur
1.
Doherty M, Dieppe P: Clinical aspects of calcium pyrophosphate dehydrate crystal deposition. Rheum Dis Clin North Am 1988, 14:395–414.PubMed
2.
•• Roddy E, Zhang W, Doherty M: Gout and nodal osteoarthritis: a case-control study. Rheumatology (Oxford) 2008, 47:732–733. This was one of the rare studies that investigated a possible relationship between gout and OA as its primary objective.CrossRef
3.
Anderson JJ, Felson DT: Factors associated with osteoarthritis of the knee in the first national Health and Nutrition Examination Survey (HANES I). Evidence for an association with overweight, race, and physical demands of work. Am J Epidemiol 1988, 128:179–189.PubMed
4.
Felson DT, Zhang Y, Anthony JM, et al.: Weight loss reduces the risk for symptomatic knee osteoarthritis in women. The Framingham Study. Ann Intern Med 1992, 116:535–539.PubMed
5.
Schouten JS, van den Ouweland FA, Valkenburg HA: A 12 year follow up study in the general population on prognostic factors of cartilage loss in osteoarthritis of the knee. Ann Rheum Dis 1992, 51:932–937.CrossRefPubMed
6.
Sun Y, Brenner H, Sauerland S, et al.: Serum uric acid and patterns of radiographic osteoarthritis—the Ulm Osteoarthritis Study. Scand J Rheumatol 2000, 29:380–386.CrossRefPubMed
7.
Acheson RM, Collart AB: New Haven survey of joint diseases. XVII. Relationship between some systemic characteristics and osteoarthrosis in a general population. Ann Rheum Dis 1975, 34:379–387.CrossRefPubMed
8.
Lally EV, Ho G Jr, Kaplan SR: The clinical spectrum of gouty arthritis in women. Arch Intern Med 1986, 146:2221–2225.CrossRefPubMed
9.
Simkin PA, Campbell PM, Larson EB: Gout in Heberden’s nodes. Arthritis Rheum 1983, 26:94–97.CrossRefPubMed
10.
Lally EV, Zimmermann B, Ho G Jr, Kaplan SR: Urate-mediated inflammation in nodal osteoarthritis: clinical and roentgenographic correlations. Arthritis Rheum 1989, 32:86–90.CrossRefPubMed
11.
Roddy E, Zhang W, Doherty M: Are joints affected by gout also affected by osteoarthritis? Ann Rheum Dis 2007, 66:1374–1377.CrossRefPubMed
12.
Laurent TC: Solubility of sodium urate in the presence of chondroitin-4-sulphate. Nature 1964, 202:1334.CrossRefPubMed
13.
Katz WA, Schubert M: The interaction of monosodium urate with connective tissue components. J Clin Invest 1970, 49:1783–1789.CrossRefPubMed
14.
Burt HM, Dutt YC: Growth of monosodium urate monohydrate crystals: effect of cartilage and synovial fluid components on in vitro growth rates. Ann Rheum Dis 1986, 45:858–864.CrossRefPubMed
15.
• Muehleman C, Li J, Aigner T, et al.: Association between crystals and cartilage degeneration in the ankle. J Rheumatol 2008, 35:1108–1117. This was a large, well-designed study investigating the prevalence, histologic, and biomechanical effects of MSU and CPP crystals on cartilage in the human ankle. A predominantly biomechanical effect was found to be induced by both MSU and CCP crystals.PubMed
16.
Malawista SE, Duff GW, Atkins E, et al.: Crystal-induced endogenous pyrogen production. A further look at gouty inflammation. Arthritis Rheum 1985, 28:1039–1046.CrossRefPubMed
17.
Di Giovine FS, Malawista SE, Nuki G, Duff GW: Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1. J Immunol 1987, 138:3213–3218.PubMed
18.
Gowen M, Wood DD, Ihrie EJ, et al.: An interleukin 1 like factor stimulates bone resorption in vitro. Nature 1983, 306:378–380.CrossRefPubMed
19.
Heath JK, Saklatvala J, Meikle MC, et al.: Pig interleukin 1 (catabolin) is a potent stimulator of bone resorption in vitro. Calcif Tissue Int 1985, 37:95–97.CrossRefPubMed
20.
Liu-Bryan R, Scott P, Sydlaske A, et al.: Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2005, 52:2936–2946.CrossRefPubMed
21.
Martinon F, Pétrilli V, Mayor A, et al.: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237–241.CrossRefPubMed
22.
Alwan WH, Dieppe PA, Elson CJ, Bradfield JW: Hydroxyapatite and urate crystal induced cytokine release by macrophages. Ann Rheum Dis 1989, 48:476–482.CrossRefPubMed
23.
Smith MD, Triantafillou S, Parker A, et al.: Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. J Rheumatol 1997, 24:365–371.PubMed
24.
Warnock MG, Sharif M, Elson CJ: IL-1-beta at physiological concentration stimulates degradation of human articular cartilage. Bone Miner 1994; 25(Suppl):S36.
25.
Liu R, Lioté F, Rose DM, et al.: Proline-rich tyrosine kinase 2 and Src kinase signaling transduce monosodium urate crystal-induced nitric oxide production and matrix metalloproteinase 3 expression in chondrocytes. Arthritis Rheum 2004, 50:247–258.CrossRefPubMed
26.
Abramson SB: Nitric oxide in inflammation and pain associated with osteoarthritis. Arthritis Res Ther 2008, 10(Suppl 2):S2.CrossRefPubMed
27.
• Liu L, Inoue H, Nakayama H, et al.: The endogenous danger signal uric acid augments contact hypersensitivity responses in mice. Pathobiology 2007, 74:177–185. This article introduced a new and important concept.CrossRefPubMed
28.
Benko S, Philpott DJ, Girardin SE: The microbial and danger signals that activate NOD-like receptors. Cytokine 2008, 43:368–373.CrossRefPubMed
29.
Gasse P, Riteau N, Charron S, et al.: Uric acid is a danger signal activating NALP3 inflammasome in lung injury inflammation and fibrosis. Am J Respir Crit Care Med 2009, 179:903–913.CrossRefPubMed
30.
Behrens MD, Wagner WM, Krco CJ, et al.: The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood 2008, 111:1472–1479.CrossRefPubMed
31.
Stabler TV, Heinrichs A, McDaniel G, et al.: Synovial fluid uric acid as a marker of joint tissue degradation in osteoarthritis [abstract]. Osteoarthr Cartil 2009, 17:S68–S69.CrossRef
32.
Zitnan D, Sitaj S: Chondrocalcinosis polyarticularis (familiaris): roentgenological and clinical analysis. Cesk Rentgenol 1960, 14:27–34.PubMed
33.
Derfus BA, Kurian JB, Butler JJ, et al.: The high prevalence of pathologic calcium crystals in pre-operative knees. J Rheumatol 2002, 29:570–574.PubMed
34.
Pattrick M, Hamilton E, Wilson R, et al.: Association of radiographic changes of osteoarthritis, symptoms, and synovial fluid particles in 300 knees. Ann Rheum Dis 1993, 52:97–103.CrossRefPubMed
35.
Neame RL, Carr AJ, Muir K, Doherty M: UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte. Ann Rheum Dis 2003, 62:513–518.CrossRefPubMed
36.
Felson DT, Anderson JJ, Naimark A, et al.: The prevalence of chondrocalcinosis in the elderly and its association with knee osteoarthritis: the Framingham Study. J Rheumatol 1989, 16:1241–1245.PubMed
37.
Sanmarti R, Kanterewicz E, Pladevall M, et al.: Analysis of the association between chondrocalcinosis and osteoarthritis: a community based study. Ann Rheum Dis 1996, 55:30–33.CrossRefPubMed
38.
Zhang Y, Terkeltaub R, Nevitt M, et al.: Lower prevalence of chondrocalcinosis in Chinese subjects in Beijing than in white subjects in the United States: the Beijing Osteoarthritis Study. Arthritis Rheum 2006, 54:3508–3512.CrossRefPubMed
39.
Silcox DC, McCarty DJ Jr: Elevated inorganic pyrophosphate concentrations in synovial fluids in osteoarthritis and pseudogout. J Lab Clin Med 1974, 83:518–531.PubMed
40.
Derfus B, Kranendonk S, Camacho N, et al.: Human osteoarthritic cartilage matrix vesicles generate both calcium pyrophosphate dihydrate and apatite in vitro. Calcif Tissue Int 1998, 63:258–262.CrossRefPubMed
41.
42.
Doherty M, Dieppe P: Clinical aspects of calcium pyrophosphate dihydrate crystal deposition. Rheum Dis Clin North Am 1988, 14:395–414.PubMed
43.
Fam AG, Morava-Protzner I, Purcell C, et al.: Acceleration of experimental lapine osteoarthritis by calcium pyrophosphate microcrystalline synovitis. Arthritis Rheum 1995, 38:201–210.CrossRefPubMed
44.
Cheung HS, Story MT, McCarty DJ: Mitogenic effects of hydroxyapatite and calcium pyrophosphate dihydrate crystals on cultured mammalian cells. Arthritis Rheum 1984, 27:668–674.CrossRefPubMed
45.
Hachicha M, Naccache PH, McColl SR: Inflammatory microcrystals differentially regulate the secretion of macrophage inflammatory protein 1 and interleukin 8 by human neutrophils: a possible mechanism of neutrophil recruitment to sites of inflammation in synovitis. J Exp Med 1995, 182:2019–2025.CrossRefPubMed
46.
• Liu YZ, Jackson AP, Cosgrove SD: Contribution of calcium-containing crystals to cartilage degradation and synovial inflammation in osteoarthritis. Osteoarthr Cartil 2009, 17:1333–1340. This was a particularly valuable study investigating the effects of synthetic and native CPP crystals on human chondrocytes and synoviocytes.CrossRefPubMed
47.
Whelan LC, Morgan MP, McCarthy GM: Basic calcium phosphate crystals as a unique therapeutic target in osteoarthritis. Front Biosci 2005, 10:530–541.CrossRefPubMed
48.
•• Fuerst M, Bertrand J, Lammers L, et al.: Calcification of articular cartilage in human osteoarthritis. Arthritis Rheum 2009, 60:2694–2703. This was a cartilage calcification study of 120 patients undergoing total knee replacement. It found BCP crystals in 100% of specimens and postulated the new idea of BCP calcification as an integral part of OA pathogenesis.CrossRefPubMed
49.
Pritzker KP: Counterpoint: Hydroxyapatite crystal deposition is not intimately involved in the pathogenesis and progression of human osteoarthritis. Curr Rheumatol Rep 2009, 11:148–153.CrossRefPubMed
50.
Oliviero F, Frallonardo P, Peruzzo L, et al.: Evidence of silicon dioxide crystals in synovial fluid of patients with osteoarthritis. J Rheumatol 2008, 35:1092–1095.PubMed
51.
Grassi W, Meenagh G, Pascual E, Filippucci E: “Crystal clear”-sonographic assessment of gout and calcium pyrophosphate deposition disease. Semin Arthritis Rheum 2006, 36:197–202.CrossRefPubMed
52.
Dalbeth N, McQueen FM: Use of imaging to evaluate gout and other crystal deposition disorders. Curr Opin Rheumatol 2009, 21:124–131.CrossRefPubMed
53.
Schueller-Weidekamm C, Schueller G, Aringer M, et al.: Impact of sonography in gouty arthritis: comparison with conventional radiography, clinical examination, and laboratory findings. Eur J Radiol 2007, 62:437–443.CrossRefPubMed
54.
Perez-Ruiz F, Martin I, Canteli B: Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol 2007, 34:1888–1893.PubMed
55.
• Thiele RG, Schlesinger N: Diagnosis of gout by ultrasound. Rheumatology (Oxford) 2007, 46:1116–1121. This article introduced specific diagnostic features for the detection of MSU crystals by ultrasonography.CrossRef
56.
Puig JG, de Miguel E, Castillo MC, et al.: Asymptomatic hyperuricemia: impact of ultrasonography. Nucleosides Nucleotides Nucleic Acids 2008, 27:592–595.CrossRefPubMed
Metadaten
Titel
The Role of Uric Acid and Other Crystals in Osteoarthritis
verfasst von
Johannes Nowatzky
Rennie Howard
Michael H. Pillinger
Svetlana Krasnokutsky
Publikationsdatum
01.04.2010
Verlag
Current Science Inc.
Erschienen in
Current Rheumatology Reports / Ausgabe 2/2010
Print ISSN: 1523-3774
Elektronische ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-010-0091-4

Weitere Artikel der Ausgabe 2/2010

Current Rheumatology Reports 2/2010 Zur Ausgabe

OriginalPaper

Imaging Lung Disease in Systemic Sclerosis

ReviewPaper

Uric Acid and Hypertension: Cause or Effect?

ReviewPaper

New Agents for the Treatment of Gout and Hyperuricemia: Febuxostat, Puricase, and Beyond

Clinical trial report

Such Sweet Sorrow: Fructose and the Incidence of Gout

ReviewPaper

Update on Biology: Uric Acid and the Activation of Immune and Inflammatory Cells

ReviewPaper

The Genetics of Juvenile Idiopathic Arthritis: What Is New in 2010?

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise